Antinflammatory therapy and cardiovascular risk: a consensus view

[Antinflammatory therapy and cardiovascular risk: a consensus view].

D. Gatti1, S. Adami2, B. Canesi2, MA. Cimmino2, O. Della Casa2, M. Del Tacca2, C. Klersy3, G. Leardini2, P. Patrignani4, L. Punzi2, S. Bombardieri2 Cattedra di Reumatologia, Università di Verona; Centro Studi SIR; Dipartimento di Biometria ed Epidemiologia Clinica, IRCCS Policlinico San Matteo, Pavia; Cattedra di Farmacologia, Dipartimento di Medicina e Scienze dell’Invecchiamento, Università “...

androgen deprivation therapy and cardiovascular risk

Testosterone therapy and cardiovascular risk.

Endogenous testosterone levels are inversely associated with cardiovascular risk in older men and men with cardiovascular disease. Current data on cardiovascular outcomes of testosterone therapy include only observational studies and adverse event monitoring in short-term trials that were not designed to measure cardiovascular outcomes. These studies have yielded conflicting results, and some h...

Renal Disease and Cardiovascular Risk: a Global View

On the other hand, it has been documented that the mortality secondary to cardiovascular disease is 10-30 times higher in chronic kidney disease patients than in the general population. This situation has been attributed to a significant increase in the prevalence of several cardiovascular risk factors: arterial hypertension, diabetes mellitus, dyslipidemia, anemia, altered calcium-phosphorus m...

Androgen Deprivation Therapy and Cardiovascular Risk

PURPOSE The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national registry to further elucidate the association between treatment selection and cause of mortality. PATIENTS AND METHODS A total of 7,248 men in the CaPSURE registry were analyzed. Treatment was categori...